

Effect of Letrozole on endometriosis-related pelvic pain

Fariba Almassinokiani¹, Alireza Almasi², Peyman Akbari³
Mahboubeh Saberifard⁴

Received: 28 April 2013

Accepted: 20 October 2013

Published: 4 October 2014

Abstract

Background: To determine the role of Letrozole, an aromatase inhibitor, in the treatment of endometriotic pain.

Methods: In this prospective, randomized, controlled clinical trial in minimally invasive surgery research center, 51 women with pelvic endometriosis and endometriotic pain (dyspareunia, dysmenorrhea, pelvic pain) score of 5 or more (for at least one of these endometriotic pain), after laparoscopic diagnosis and conservative laparoscopic surgery were treated with either Letrozole plus OCP (n=25) or only OCP (n=26) for 4 months continuously.

Results: Using VAS test, the score of dyspareunia, dysmenorrhea and pelvic pain 4 months after the laparoscopic surgery declined significantly in both groups but the difference between results of the two groups was not significant.

Conclusion: Both treatment modalities showed comparable effectiveness in the treatment of pains related to endometriosis and in comparison with OCP, Letrozole did not affect the outcome.

Keywords: Aromatase inhibitor, Endometriosis, Letrozole, Pelvic pain.

Cite this article as: Almassinokiani F, Almasi A, Akbari P, Saberifard M. Effect of Letrozole on endometriosis-related pelvic pain. *Med J Islam Repub Iran* 2014 (4 October). Vol. 28:107.

Introduction

Presence of endometrial glandular and stromal cells outside the uterine cavity is called endometriosis which can be diagnosed by visual inspection of the pelvis during laparoscopy. The most common manifestations of endometriosis are dyspareunia, dysmenorrhea, pelvic pain and infertility that can have important effects on the quality of life (1,2). Endometriosis is an estrogen dependent disease (3,4) and estradiol supports growth and inflammation process in endometriotic lesions (2,5). Almost all treatments for endometriosis (GNRH agonists, progestins, danazol,

OCP) have an effect on endometriosis by decreasing ovarian estrogen levels or antagonize estrogen.

In women, another estrogen source is androgen change into estrogen in peripheral tissues by aromatase P 450 enzyme (1,6). Aromatase is a key enzyme in the synthesis of estrogens. Aromatization is the last step in estradiol biosynthesis (3). Aromatase mediates the conversion of androstendione and testosterone to estrogens. Perhaps inhibition of aromatase enzyme and decreasing the peripheral conversion of androgens to estrogen could have a therapeutic effect as inhibition of endometriotic foci. Letrozole

1. Associate Professor, Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Department of gynecology and obstetrics, Rasool Akram Hospital, Tehran, Iran. dralmassi@yahoo.com

2. (Corresponding author) Assistant Professor, Iran University of Medical Sciences, Firoozgar Hospital, Tehran, Iran. a_almasi_n@hotmail.com

3. Medical Student, Tehran University of Medical Sciences, Department of gynecology and obstetrics, Rasool Akram Hospital, Tehran, Iran. thekingofkings_angle@yahoo.com

4. Resident of Gynecology, Iran University of Medical Sciences, Department of Gynecology and Obstetrics, Rasool Akram Hospital, Tehran, Iran. msaberi@hyhoo.com

is a drug that can inhibit aromatase enzyme and in some studies on animal models (rats, mice and baboons) it has led to the reduction in the size of endometriotic implants (7-10). Letrozole is a drug that inhibits the aromatase enzyme by competitively binding to the cytochrome P 450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Elevated levels of aromatase have been found in endometriotic lesions (11). Therefore, aromatase inhibitors maybe effective in treating endometriosis related pelvic pain.

Methods

This study was conducted as a randomized controlled trial to assess the effect of Letrozole on pain due endometriosis. As Letrozole can activate ovulation and is also a teratogen (12), during its use the patient must take contraception. We prescribed Letrozole in combination with OCP in one group and in the control group we prescribed OCP only. Our sample was composed of the patients with at least one kind of endometriotic pain (dyspareunia, dysmenorrhea, pelvic pain) who were diagnosed as endometriotic by laparoscopy. Laparoscopy was performed under general anesthesia using the triple puncture technique. On laparoscopy, the surgeon tried to excise or ablate all the endometriotic implants and adhesiolysis was also performed. The day before laparoscopy, a data collection form was filled by a physician. The severity of dyspareunia, dysmenorrhea and pelvic pain was estimated by Visual Analogue Scale test (VAS test). Scale 0 was no pain and 10 was the most severe pain ever experienced. Those patients who had the score of 5 or more before the operation for one of their painful symptoms (dyspareunia, dysmenorrhea, pelvic pain) were included in our study. After operation, the severity of endometriosis was written in the data collection form as revised American Society for Reproductive Medicine classification (ASRM) scores for endometriosis (1,13).

With the acceptance of ethic committee

of Tehran University of Medical Sciences and obtaining informed consent in cases of Letrozole prescription, we prescribed OCP (Levonorgestrel 0.15 mg plus Ethinyl Estradiol 0.03 mg, Iran Hormon, Tehran, Iran) daily for 4 months continuously in control group and OCP in combination with oral Letrozole (Femara, 2.5 mg-Novartis-Switzerland) daily for 4 months continuously in another group. Both groups took vitamin D 400IU plus Calcium 1 gram (Schiff, USA) daily for 4 months. All of the samples were the patients who had not planned to become pregnant after discharge. We randomized the patients by assigning to the case and control groups alternately in the order of their admission. Patients were evaluated at one and four months after operation and after starting medical treatment by office visits and telephone inquiry for severity of their endometriotic pain and drug compliance. The patients did not have any other medical or systemic diseases. Before initiation of treatment, liver function tests, serum urea, creatinin, lipids and plasma glucose were checked.

We analyzed the data by SPSS 13, using the KS test (One-sample Kolmogorov-Smirnov test) for normality of data distribution, Levene's test for equality of variances and independent samples t-test for equality of means for comparing quantitative normal data between two groups, paired sample t-tests for comparing quantitative normal data between before and after treatment in each group and Pearson Chi-square test for matching and comparing categorical variables between two groups. According to the KS test, we compared the non-normal quantitative data by Mann-Whitney U nonparametric test between two groups and Wilcoxon Signed Ranks test for comparing before and after treatment data in each group. The categorical variables, before and after medical treatment were analyzed by Mc Nemar test.

Results

In this study we had 25 patients in Letro-

Table 1. comparison of age and severity of pain in two groups before and after treatment

	Treatment Group	N	Mean	p value
Age	Letrozole	25	31.0000	0.018
	OCP	26	27.5385	0.019
Dysmenorrhea score before treatment	Letrozole	25	7.2000	0.599
	OCP	26	7.5000	0.600
Dypareunia score before treatment	Letrozole	15	4.8000	0.490
	OCP	14	5.5714	0.491
Noncyclic pelvic pain score before treatment	Letrozole	25	6.3200	0.460
	OCP	26	5.8077	0.461
Dysmenorrhea score 4 month after treatment	Letrozole	25	1.1200	0.050
	OCP	26	1.3846	0.049
Dypareunia score 4 month after treatment	Letrozole	14	1.8571	0.631
	OCP	14	2.0000	0.631
Noncyclic pelvic pain score 4 month after treatment	Letrozole	24	1.9583	0.055
	OCP	26	2.5000	0.058

zole plus OCP group (L group) and 26 patients in OCP group (O group). The age range was 20 - 43 years old. 10 patients from L group and 12 patients from O group were single and had not sexual contact. The patients in the L group were matched with O group for marital status, severity of endometriosis and severity of pelvic pain so that there had been no significant differences (Table 1).

All the patients reported improvement in the pain score within one month and four months of initiation of medical treatment. The pain scores continued to decrease during the course of the treatment. All of the

patients developed amenorrhea after initiation of therapy and none of them had bone pain.

There was no significant difference in severity of dyspareunia, dysmenorrhea and pelvic pain between the two groups before and after treatment, but after treatment the severity of the 3 mentioned symptoms was significantly reduced in both groups in comparison with their pretreatment status (Table 1,5).

None of the patients developed any side-effects of Letrozole or OCP and all continued the prescribed medication for 4 months.

Table 2. severity of pelvic pain in two groups before treatment

			Treatment Group		Total
			Letrozole	OCP	
Noncyclic pelvic pain score before treatment	1.00	Count	2	2	4
		percent	50.0%	50.0%	100.0%
	2.00	Count	1	0	1
		percent	100.0%	.0%	100.0%
	3.00	Count	0	3	3
		percent	.0%	100.0%	100.0%
	4.00	Count	0	1	1
		percent	.0%	100.0%	100.0%
	5.00	Count	7	5	12
		percent	58.3%	41.7%	100.0%
	6.00	Count	5	3	8
		percent	62.5%	37.5%	100.0%
	7.00	Count	0	6	6
		percent	.0%	100.0%	100.0%
	8.00	Count	5	4	9
		percent	55.6%	44.4%	100.0%
Total	9.00	Count	1	1	2
		percent	50.0%	50.0%	100.0%
	10.00	Count	4	1	5
		percent	80.0%	20.0%	100.0%
		Count	25	26	51
		percent	49.0%	51.0%	100.0%

Table 3. severity of dyspareunia in two groups before treatment

			Treatment Group		Total
			Letrozole	OCP	
Dyspareunia score before treatment	1.00	Count	4	2	6
		percent	66.7%	33.3%	100.0%
	2.00	Count	0	1	1
		percent	.0%	100.0%	100.0%
	3.00	Count	0	1	1
		percent	.0%	100.0%	100.0%
	4.00	Count	3	0	3
		percent	100.0%	.0%	100.0%
	5.00	Count	2	4	6
		percent	33.3%	66.7%	100.0%
	6.00	Count	1	0	1
		percent	100.0%	.0%	100.0%
	7.00	Count	3	0	3
		percent	100.0%	.0%	100.0%
	8.00	Count	0	4	4
		percent	.0%	100.0%	100.0%
	9.00	Count	1	1	2
		percent	50.0%	50.0%	100.0%
Total	10.00	Count	1	1	2
		percent	50.0%	50.0%	100.0%
			Count	15	14
			percent	51.7%	48.3%
					100.0%

Table 4. severity of dysmenorrhea in two groups before treatment

			Treatment Group		Total
			Letrozole	OCP	
Dysmenorrhea score before treatment	1.00	Count	0	1	1
		percent	.0%	100.0%	100.0%
	3.00	Count	2	0	2
		percent	100.0%	.0%	100.0%
	4.00	Count	1	0	1
		percent	100.0%	.0%	100.0%
	5.00	Count	2	2	4
		percent	50.0%	50.0%	100.0%
	6.00	Count	5	2	7
		percent	71.4%	28.6%	100.0%
	7.00	Count	2	5	7
		percent	28.6%	71.4%	100.0%
	8.00	Count	6	10	16
		percent	37.5%	62.5%	100.0%
	9.00	Count	2	3	5
		percent	40.0%	60.0%	100.0%
	10.00	Count	5	3	8
		percent	62.5%	37.5%	100.0%
Total		Count	25	26	51
		percent	49.0%	51.0%	100.0%

Discussion

The major finding of this prospective, randomized trial of Letrozole plus OCP versus OCP in the treatment of endometriotic pelvic pain after ablative surgery was that there was no significant difference in outcome between the two groups and the results of both treatment modalities were similar.

The highest level of aromatase in premenopausal women is in ovary. There

are observations of increased expression of aromatase P 450 in endometriotic tissues (11,14-16) and aromatase inhibitors had been successful in regressing endometriotic tissue (17) and decreasing pelvic pain (17-22).

In a retrospective study by Abushahin et al. on 16 patients with endometriosis and chronic pelvic pain Letrozole 2.5 mg plus norethindrone acetate 2.5mg daily for 6 months improved pain symptoms, however

Table 5. Paired Samples Test (pain scores before treatment and 4 months after start of treatment in Letrozole group)

Table 5: Paired Samples Test (pain scores before treatment and 4 months after start of treatment in Electrozone group)						
	Mean	Std. Deviation	Paired Differences		t	sig
			95% Confidence Interval of the Difference			
			Lower	Upper		
Dysmenorrhea score before treatment - Dysmenorrhea score 4 month after start of treatment	6.08000	2.03961	5.23809	6.92191	14.905	.000
Dyspareunia score before treatment - Dyspareunia score 4 month after start of treatment	3.21429	2.32639	1.87107	4.55750	5.170	.000
Noncyclic pelvic pain score before treatment - Noncyclic pelvic pain score 4 month after start of treatment	4.37500	2.44616	3.34208	5.40792	8.762	.000

Treatment Group = Letrozole

Table 6. Paired Samples Test (pain scores before treatment and 4 months after start of treatment in OCP group)

Table 6: Paired Samples Test (pain scores before treatment and 4 months after start of treatment in OCP group)						
	Mean	Std. Deviation	Paired Differences		t	sig.
			95% Confidence Interval of the Difference			
			Lower	Upper		
Dysmenorrhea score before treatment -Dysmenorrhea score 4 month after start of treatment	6.11538	1.79615	5.38990	6.84087	17.361	.000
Dyspareunia score before treatment - Dyspareunia score 4 month after start of treatment	3.57143	3.00549	1.83611	5.30675	4.446	.001
Noncyclic pelvic pain score before treatment - Noncyclic pelvic pain score 4 month after start of treatment	3.30769	1.91351	2.53481	4.08058	8.814	.000

Treatment Group = OCP

pain recurred after treatment was completed (19). In another study by Verma et al. on 4 premenopausal women with endometriosis prescription of 2.5mg Letrozole plus 2.5mg norethisterone daily for 6 months, the mean pain score fell from 9 prior to the treatment to 4.5 at the end of treatment (4). In a prospective study by Ailawadi et al. on 10 patients with endometriosis and chronic pelvic pain, they prescribed 2.5mg per day Letrozole plus norethindrone for 6 months and after that they did a second-look laparoscopy. On laparoscopy, there was no histologic evidence of endometriosis and pelvic pain score decreased significantly in response to treatment (17). In a study by Amsterdam et al., Anastrozole and OCP continuously for 6 months made reduction of pain in 93% of cases (23). In a study by Seal et al., 5 patients with ovarian endometrioma used letrozole, 2.5mg per day plus OCP for 6 months and they found disappearance of ovarian endometrioma and reduction of pain scores (24).

We did not use Letrozole with progestins because of break through bleeding and that they could not make adequate contraceptive effect (because Letrozole is teratogen and during its use, the patient must have effective contraception. In our study, the results of OCP prescription for endometriotic pain in comparison with Letrozole plus OCP were similar.

Limitations

1. We prescribed Letrozole in combination with OCP and the pain reduced significantly, but it is not known that the reduction in pain severity is due to OCP as a standard regimen for endometriosis or due to Letrozole itself or synergistic effect of the two. Therefore, we suggest another study to be conducted using larger sample sizes on single sexually inactive women to know the isolated effect of Letrozole on pelvic pain and dysmenorrhea secondary to endometriosis.

2. We did not perform a second-look lap-

aroscopy to determine the effect of treatment on the size of endometriotic lesions. Of course it is possible that Letrozole has a reductive effect on the size of the endometriotic lesion without significant reduction in severity of subjective pain experience in patients, because the severity of symptoms is not directly related to the severity of endometriosis (1).

Conclusion

The outcomes of 2 groups were similar so we may conclude that Letrozole had not any positive effect on decreasing endometriotic pain.

References

1. D'Hooghe TM. Endometriosis in: JS. Berek. Berek & Novak's gynecology. 15th ed. Lippincott Williams & Wilkins. 2012; Pp 505-57.
2. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010 Jun 24; 362(25):2389-98.
3. Pavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil Steril. 2012 Dec; 98(6):1370-9.
4. Verma A, Konje JC. Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients. Eur J Obstet Gynecol Reprod Biol. 2009 Apr; 143(2):112-5.
5. Giudice LC, Kao LC. Endometriosis. Lancet. 2004 Nov 13-19;364(9447):1789-99.
6. Agarwal VR, Ashanullah CI, Simpson ER, Bulun SE. Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women. J Clin Endocrinol Metab. 1997 Jan; 82(1):70-4.
7. Ceyhan ST, Onguru O, Fidan U, Ide T, Yaman H, Kilic S, Baser I. Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model. Eur J Obstet Gynecol Reprod Biol. 2011 Jan;154(1):100-4.
8. Oner G, Ozcelik B, Ozgun MT, Serin IS, Ozturk F, Basbug M. The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. Hum Reprod. 2010 Apr;25(4):932-7.
9. Bilotas M, Meresman G, Stella I, Sueldo C, Baraño RI. Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis. Fertil Steril. 2010 May 15;93(8):2513-8.
10. Langoi D, Pavone ME, Gurates B, Chai D, Fazleabas A, Bulun SE. Aromatase inhibitor treatment limits progression of peritoneal endometriosis in baboons. Fertil Steril. 2012 Dec 17. pii: S0015-0282(12)02433-8.
11. Attar E, Tokunaga H, Imir G, Yilmaz MB, Redwine D, Putman M, et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab. 2009 Feb;94(2):623-31.
12. Gill SK, Moretti M, Koren G. Is the use of letrozole to induce ovulation teratogenic? Can Fam Physician. 2008 Mar;54(3):353-4.
13. Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011 Feb;95(2):492-6.
14. Ferrero S, Venturini PL, Ragni N, Camerini G, Remorgida V. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs. 2009 May 29;69(8):943-52.
15. Remorgida V, Abbamonte LH, Ragni N, Fulcheri E, Ferrero S. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust N Z J Obstet Gynaecol. 2007 Jun; 47(3):222-5.
16. Bulun SE, Fang Z, Imir G, Gurates B, Tamura M, Yilmaz B, et al. Aromatase and endometriosis. Semin Reprod Med. 2004 Feb;22(1):45-50.
17. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. 2004 Feb; 81(2):290-6.
18. Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril. 2004 May;81(5):1395-8.
19. Abushahin F, Goldman KN, Barbieri E, Milad M, Rademaker A, Bulun SE. Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. Fertil Steril. 2011 Oct;96(4):939-42.
20. Remorgida V, Abbamonte HL, Ragni N, Fulcheri E, Ferrero S. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril. 2007 Sep;88(3):724-6.
21. Ferrero S, Camerini G, Ragni N, Venturini PL, Biscaldi E, Seracchioli R, et al. Letrozole and norethisterone acetate in colorectal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010 Jun; 150(2):199-202.
22. Ferrero S, Camerini G, Seracchioli R, Ragni N, Venturini PL, Remorgida V. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009 Dec;24(12):3033-41.
23. Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrozole and oral contraceptives: a novel treatment for endometriosis.

Fertil Steril. 2005 Aug;84(2):300-4.

24. Lall Seal S, Kamilya G, Mukherji J, De A, Ghosh D, Majhi AK. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases

with literature review. Fertil Steril. 2011 Jan; 95(1):291.e15-8.doi: 10.1016/j.fertnstert.2010.05.021. Epub 2010 Jun 25.